Intravitreal inj Wet AMD 2 mg (equiv to 50 microL). Initiated w/ 1 inj/mth for 3 consecutive mth, followed by 1 inj every 2 mth. Treatment interval may be maintained at 2 mth or further extended using a treat-&-extend dosing regimen.
ME secondary to CRVO 2 mg (equiv to 50 microL). After initial inj, treatment is given mthly (every 4 wk) until visual &/or anatomic outcomes are stable for ≥3 mthly inj, interval between 2 doses should not be shorter than 1 mth. Continue treatment & the interval may be extended based on visual & anatomic outcomes (treat & extend regimen).
ME secondary to BRVO 2 mg (equiv to 50 microL). After initial inj, treatment is given mthly (every 4 wk) until visual &/or anatomic outcomes are stable for ≥3 mthly inj, interval between 2 doses should not be shorter than 1 mth. Continue treatment & the interval may be extended based on visual & anatomic outcomes (treat & extend regimen).
DME 2 mg (equiv to 50 microL) mthly for the 1st 5 consecutive doses, followed by 1 inj every 2 mth. After the 1st 12 mth, & based on visual &/or anatomic outcomes, treatment interval may be extended such as w/ a treat-&-extend dosing regimen.
Myopic CNV 2 mg (equiv to 50 microL) as a single inj. Additional doses only if disease persists.